F1000Res. 2019 Dec 13;8:F1000 Faculty Rev-2097.doi: 10.12688/f1000research.19609.1. eCollection 2019.

Bhaskar Gurram ¹, Ashish S Patel ¹

Author information

• ¹University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Abstract

The landscape of pediatric inflammatory bowel disease is rapidly evolving. The therapeutic advances seen in the adult arena are rapidly being adopted by pediatric gastroenterologists and evaluated in both controlled trials and real-world experience. Though anti-tumor necrosis factor agents have been the primary therapy over the last decade, recently there has been an expansion of therapeutic targets and alternative mechanism of action drugs with a focus on individualized and personalized therapy. By reviewing epidemiology, pathophysiology, and goals of treatment, we hope to frame the discussion of current and novel therapeutics for the pediatric gastroenterologist. As scientific discovery continues to push the envelope in defining our understanding of pediatric inflammatory bowel disease, the current era of therapeutics gives us hope that a cure may be realized soon.